Cargando…

The potential of lasmiditan in migraine

Lasmiditan, a highly selective 5-hydroxytryptamine receptor 1F (5-HT(1F)) agonist, is the first drug in its class and is lacking triptan-like vasoactive properties. The US Food and Drug Administration (FDA) has recently approved lasmiditan for the acute treatment of migraine in adults based on posit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mecklenburg, Jasper, Raffaelli, Bianca, Neeb, Lars, Sanchez del Rio, Margarita, Reuter, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739205/ https://www.ncbi.nlm.nih.gov/pubmed/33403005 http://dx.doi.org/10.1177/1756286420967847

Ejemplares similares

Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis
por: Overeem, Lucas Hendrik, et al.
Publicado: (2021)

Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
por: Raffaelli, Bianca, et al.
Publicado: (2020)

Patients’ and Health Care Workers’ Perception of Migraine Images on the Internet: Cross-sectional Survey Study
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies
por: Terhart, Maria, et al.
Publicado: (2021)

Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
por: Raffaelli, Bianca, et al.
Publicado: (2022)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Plasma calcitonin gene‐related peptide (CGRP) in migraine and endometriosis during the menstrual cycle
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Primary headaches during the COVID-19 lockdown in Germany: analysis of data from 2325 patients using an electronic headache diary
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan
por: Rizzoli, Paul B
Publicado: (2014)

Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
por: Oswald, Jessica C, et al.
Publicado: (2018)

Determining the Evolution of Headache Among Regular Users of a Daily Electronic Diary via a Smartphone App: Observational Study
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Lasmiditan: A New Promising Drug in Migraine
por: Prakash, Sanjay, et al.
Publicado: (2021)

Efficacy of lasmiditan for the acute treatment of perimenstrual migraine
por: MacGregor, E Anne, et al.
Publicado: (2022)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study
por: Ashina, Messoud, et al.
Publicado: (2021)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine
por: Tsai, Max, et al.
Publicado: (2021)

The influence of weather on migraine – are migraine attacks predictable?
por: Hoffmann, Jan, et al.
Publicado: (2015)

Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy
por: Anderson, Christopher C, et al.
Publicado: (2023)

Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study
por: Overeem, Lucas Hendrik, et al.
Publicado: (2021)

Budget impact of lasmiditan for the acute treatment of migraine in the United States
por: Milev, Sandra, et al.
Publicado: (2021)

Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience
por: Blumenfeld, Andrew, et al.
Publicado: (2023)

Characteristics and diagnoses of acute headache in pregnant women – a retrospective cross-sectional study
por: Raffaelli, Bianca, et al.
Publicado: (2017)

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
por: Knievel, Kerry, et al.
Publicado: (2019)

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
por: Krege, John H., et al.
Publicado: (2022)

Optimal Dosing of Lasmiditan in the Management of Acute Migraine Attack: A Systematic Review and Meta-analysis
por: Basutkar, Roopa Satyanarayan, et al.
Publicado: (2021)

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
por: Kuca, Bernice, et al.
Publicado: (2018)

Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial
por: Takeshima, Takao, et al.
Publicado: (2022)

European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention – part 3: topiramate
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study
por: Lipton, Richard B., et al.
Publicado: (2020)

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
por: Goadsby, Peter J, et al.
Publicado: (2019)

Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

The Effect and Safety of 5-HT(1F) Receptor Agonist Lasmiditan on Migraine: A Systematic Review and Meta-Analysis
por: Gu, Ping, et al.
Publicado: (2021)

Study Design and Protocol of a Randomized Controlled Trial of the Efficacy of a Smartphone-Based Therapy of Migraine (SMARTGEM)
por: Oliveira Gonçalves, Ana Sofia, et al.
Publicado: (2022)

Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks
por: Tepper, Stewart J., et al.
Publicado: (2020)

Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine
por: Tassorelli, C, et al.
Publicado: (2021)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
por: Polavieja, Pepa, et al.
Publicado: (2022)

The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials
por: Tfelt-Hansen, Peer C., et al.
Publicado: (2012)

Two TRPV1 receptor antagonists are effective in two different experimental models of migraine
por: Meents, Jannis E, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f2hue70pgj87btt2i0mobnqdn9